576
MICROBIOTA-INDUCED S100A11-RAGE AXIS UNDERLIES IMMUNOEVASION IN RIGHT-SIDED COLON ADENOMAS AND IS A THERAPEUTIC TARGET TO BOOST ANTI-PD1 EFFICACY
Date
May 19, 2024
Tracks
Related Products
<i>LACTOCOCCUS LACTIS </i>SUPPRESSES COLORECTAL TUMORIGENESIS BY RESTORING GUT MICROBIOME COMPOSITION AND GENERATING BENEFICIAL ALPHA- MANNOSIDASE
BACKGROUND: Through shotgun metagenomic sequencing, we identified the depletion of probiotic species_ Lactobacillus acidophilus_ in stools of mice with non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC)…
FUSOBACTERIUM NUCLEATUM FACILITATES ANTI-PD-1 THERAPY IN MICROSATELLITE STABLE COLORECTAL CANCER
BACKGROUND: Around 80-85% of colorectal cancer (CRC) belongs to ‘immune cold’ microsatellite stable (MSS) subtype without responsive to anti-PD-1 mAb therapy…
IMMUNE EVASION OF COLORECTAL CANCER STEM CELLS IS DEPENDENT ON SLC25A22-MEDIATED WNT SIGNALING
Colonoscopy surveillance intervals are based on the predicted risk of metachronous colorectal cancer (CRC) after polyp removal. Due to the presence of co-existent findings at baseline colonoscopy, risk estimation per specific polyp subtype is difficult…
<i>PEPTOSTREPTOCOCCUS STOMATIS</i> PROMOTES COLORECTAL TUMORIGENESIS AND TYROSINE KINASE INHIBITOR RESISTANCE THROUGH ALTERNATIVE ACTIVATION OF ERBB2
BACKGROUND AND AIMS: Peptostreptococcus stomatis (_P. stomatis_) is an enriched bacterium in colorectal cancer (CRC) patients as compared to healthy subjects in multiple cohorts. However, the potential role of _P. stomatis_ in colorectal tumorigenesis remains obscure…